Study identifier:BY9010/M1-137
ClinicalTrials.gov identifier:NCT00163397
EudraCT identifier:N/A
CTIS identifier:N/A
A comparative study of inhaled ciclesonide 160 mcg/day vs budesonide 400 mcg/day in patients with asthma
asthma
Phase 3
No
Ciclesonide
All
120
Interventional
18 Years - 75 Years
Allocation: Randomized 
Endpoint Classification: Safety/Efficacy Study 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Treatment 
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|